KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Assets (2016 - 2025)

Historic Current Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $3.9 billion.

  • Biomarin Pharmaceutical's Current Assets rose 2610.6% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 2610.6%. This contributed to the annual value of $3.2 billion for FY2024, which is 934.81% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Current Assets stood at $3.9 billion for Q3 2025, which was up 2610.6% from $3.8 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Current Assets high stood at $3.9 billion for Q3 2025, and its period low was $2.3 billion during Q4 2021.
  • Moreover, its 5-year median value for Current Assets was $3.0 billion (2023), whereas its average is $2.9 billion.
  • Its Current Assets has fluctuated over the past 5 years, first tumbled by 1560.47% in 2021, then skyrocketed by 2610.6% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Current Assets (Quarter) stood at $2.3 billion in 2021, then grew by 20.98% to $2.8 billion in 2022, then grew by 7.44% to $3.0 billion in 2023, then rose by 9.35% to $3.2 billion in 2024, then rose by 19.25% to $3.9 billion in 2025.
  • Its last three reported values are $3.9 billion in Q3 2025, $3.8 billion for Q2 2025, and $3.5 billion during Q1 2025.